187 related articles for article (PubMed ID: 1381912)
21. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.
Kuhöber A; Pudollek HP; Reifenberg K; Chisari FV; Schlicht HJ; Reimann J; Schirmbeck R
J Immunol; 1996 May; 156(10):3687-95. PubMed ID: 8621903
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.
Fuller DH; Shipley T; Allen TM; Fuller JT; Wu MS; Horton H; Wilson N; Widera G; Watkins DI
Virology; 2007 Aug; 364(2):245-55. PubMed ID: 17428516
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco.
Huang Y; Liang W; Wang Y; Zhou Z; Pan A; Yang X; Huang C; Chen J; Zhang D
Viral Immunol; 2005; 18(4):668-77. PubMed ID: 16359233
[TBL] [Abstract][Full Text] [Related]
24. [Antigenic analysis of two chimeric hepatitis B core particles presenting the preS1 neutralizing epitopes].
Su QD; Guo MZ; Yi Y; Chen SY; Jia ZY; Lu XX; Qiu F; Bi SL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Oct; 27(5):336-9. PubMed ID: 24645316
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 derived peptides fused to HBsAg affect its immunogenicity.
Gonzalez MC; Kostrzak A; Guetard D; Pniewski T; Sala M
Virus Res; 2009 Dec; 146(1-2):107-14. PubMed ID: 19766153
[TBL] [Abstract][Full Text] [Related]
26. [Experimental molecular design of recombinant vaccines].
Lebedev LR; Goncharova EP; Sizov AA; Bulychev LE; Odegov AM; Ryzhikov AB
Mol Biol (Mosk); 2003; 37(3):544-9. PubMed ID: 12815963
[TBL] [Abstract][Full Text] [Related]
27. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X; Li M; Le X; Ma W; Zhou B
Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of peptide fusions to hepatitis B virus core antigen.
Stahl SJ; Murray K
Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6283-7. PubMed ID: 2474830
[TBL] [Abstract][Full Text] [Related]
29. Design of immunogens as components of a new generation of molecular vaccines.
Loktev VB; Ilyichev AA; Eroshkin AM; Karpenko LI; Pokrovsky AG; Pereboev AV; Svyatchenko VA; Ignat'ev GM; Smolina MI; Melamed NV; Lebedeva CD; Sandakhchiev LS
J Biotechnol; 1996 Jan; 44(1-3):129-37. PubMed ID: 8717396
[TBL] [Abstract][Full Text] [Related]
30. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
31. [Humoral immune response of BALB/c mice immunized with chimer HBcAg proteins carrying the epitopes of surface hepatic B virus protein].
Veremeĭko TA; Lebedev LR; Chikaev NA; Il'ichev AA; Karpenko LI
Vopr Virusol; 2007; 52(1):40-5. PubMed ID: 17338233
[TBL] [Abstract][Full Text] [Related]
32. Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines.
Schödel F; Kelly SM; Peterson D; Milich D; Hughes J; Tinge S; Wirtz R; Curtiss R
Dev Biol Stand; 1994; 82():151-8. PubMed ID: 7958469
[TBL] [Abstract][Full Text] [Related]
33. [Expression of HIV-1 epitopes included in particles formed by human hepatitis B virus nucleocapsid protein].
Isaguliants MG; Kadoshnikov IuP; Kalinina TI; Khuliakov IuE; Semiletov IuA; Smirnov VD; Wahren B
Biokhimiia; 1996 Mar; 61(3):532-45. PubMed ID: 8724609
[TBL] [Abstract][Full Text] [Related]
34. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface.
Borisova GP; Berzins I; Pushko PM; Pumpen P; Gren EJ; Tsibinogin VV; Loseva V; Ose V; Ulrich R; Siakkou H
FEBS Lett; 1989 Dec; 259(1):121-4. PubMed ID: 2480917
[TBL] [Abstract][Full Text] [Related]
35. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein.
Clarke BE; Newton SE; Carroll AR; Francis MJ; Appleyard G; Syred AD; Highfield PE; Rowlands DJ; Brown F
Nature; 1987 Nov 26-Dec 2; 330(6146):381-4. PubMed ID: 2446137
[TBL] [Abstract][Full Text] [Related]
36. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
37. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
38. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.
Chen JY; Li F
World J Gastroenterol; 2006 Dec; 12(48):7774-8. PubMed ID: 17203519
[TBL] [Abstract][Full Text] [Related]
39. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts.
Jechlinger W; Haller C; Resch S; Hofmann A; Szostak MP; Lubitz W
Vaccine; 2005 May; 23(27):3609-17. PubMed ID: 15855021
[TBL] [Abstract][Full Text] [Related]
40. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
Yang BF; Zhao HL; Xue C; Xiong XH; Zhang W; Yao XQ; Liu ZM
Vaccine; 2007 May; 25(22):4478-86. PubMed ID: 17467856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
